CU Anschutz Lymphoma Program (@CULymphoma) header
CU Anschutz Lymphoma Program (@CULymphoma) profile picture

The official account for the @CUMedicalSchool @CUAnschutz Lymphoma Program. #lymsm

Denver, CO
Joined September 2022
Photo by CU Anschutz Lymphoma Program (@CULymphoma)Photo by CU Anschutz Lymphoma Program (@CULymphoma)Photo by CU Anschutz Lymphoma Program (@CULymphoma)Photo by CU Anschutz Lymphoma Program (@CULymphoma)Photo by CU Anschutz Lymphoma Program (@CULymphoma)Photo by CU Anschutz Lymphoma Program (@CULymphoma)Photo by CU Anschutz Lymphoma Program (@CULymphoma)Photo by CU Anschutz Lymphoma Program (@CULymphoma)Photo by CU Anschutz Lymphoma Program (@CULymphoma)Photo by CU Anschutz Lymphoma Program (@CULymphoma)
Our @CUHematology website features all of our open B- and T-cell lymphoma and cellular therapy clinical trials, by Drs. @mana1981, @BradHaverkos, @StevenBairMD and @majorajay. #lymsm #clinicaltrials medschool.cuanschutz.edu/hem…
1
4
11
1,618
CU Anschutz Lymphoma Program retweeted
🚨Calling all mantle cell lymphoma clinicians🚨 redcap.link/MCLSurvey Please take our quick <10 minute survey - 7 short management cases - we want to hear your treatment preferences! You can answer as if able to access any therapy at any time. #ASH26 #lymsm
1
6
14
1,311
Our @CULymphoma lead Dr. @mana1981 and @CUInternalMed chief Dr. @vpizzuti44 contributed to a multicenter study on CAR-T vs ASCT in second-line PMBCL, now published @BloodAdvances. #lymsm #bmtsm ashpublications.org/bloodadv…
2
8
328
CU Anschutz Lymphoma Program retweeted
Love working with this diverse group of #lymsm clinician-scientists at @CUAnschutz @CUHematology! We are looking forward to seeing you all at @ASH_hematology #ASH26. cc @mana1981 @BradHaverkos @StevenBairMD @cduarte8490
It's been a busy year for our @CULymphoma faculty! Let's preview our abstracts and presentations at the upcoming @ASH_hematology #ASH26 Annual Meeting in December! First, Dr. @mana1981 is giving a prestigious Education Program talk on non-T-cell engaging therapies for FL. #lymsm
1
2
8
1,011
It's been a busy year for our @CULymphoma faculty! Let's preview our abstracts and presentations at the upcoming @ASH_hematology #ASH26 Annual Meeting in December! First, Dr. @mana1981 is giving a prestigious Education Program talk on non-T-cell engaging therapies for FL. #lymsm
1
1
1
13
1,595
Dr. @majorajay has several abstracts as part of the @SWOG Lymphoma Committee & the CUBIC Consortium, as well as posters on patient-reported outcomes in NLPHL and myeloma. He is also moderating an oral session (w/ @heMEGirl_MD) on toxicities & late effects after #lymsm treatment.
1
2
7
356
Our rare disease expert Dr. @cduarte8490 has several abstracts on #lymsm outcomes with bispecific antibodies, including a first-author abstract from the CUBIC Consortium and a senior-author abstract in rare LBCL histologies. #lymsm #ASH26
2
125
CU Anschutz Lymphoma Program retweeted
Great work by @majorajay adding yet another factor (time toxicity) helping clinicians on deciding between two very effective therapies in FL.
Excited to share our new @BloodPortfolio manuscript comparing CAR-T vs BsAb in R/R FL. In addition to comparing survival, we also studied "time toxicity," or how much time patients spend physically interacting with the healthcare system. #lymsm 🧵 ashpublications.org/bloodadv…
1
2
5
617
CU Anschutz Lymphoma Program retweeted
Comparative survival and time toxicity outcomes of CAR-T versus bispecific antibody therapies in relapsed/refractory FL ashpublications.org/bloodadv… #lymsm
10
32
2,039
CU Anschutz Lymphoma Program retweeted
Establishing a benchmark to help physicians counsel patients with follicular lymphoma (FL) on the expected time toxicity associated with CAR T-cell therapy versus bispecific antibody (BiTE) therapy. Full article link doi.org/10.1182/bloodadvance…
2
4
15
1,314
Congratulations to our junior @CUHematology faculty on publication of this multicenter study comparing survival and time toxicity outcomes between CAR-T and bispecific antibodies in follicular lymphoma! #lymsm #tcellrx cc @BloodPortfolio @CUMedicalSchool @CUAnschutz
Excited to share our new @BloodPortfolio manuscript comparing CAR-T vs BsAb in R/R FL. In addition to comparing survival, we also studied "time toxicity," or how much time patients spend physically interacting with the healthcare system. #lymsm 🧵 ashpublications.org/bloodadv…
1
5
395
CU Anschutz Lymphoma Program retweeted
Excited to share our new @BloodPortfolio manuscript comparing CAR-T vs BsAb in R/R FL. In addition to comparing survival, we also studied "time toxicity," or how much time patients spend physically interacting with the healthcare system. #lymsm 🧵 ashpublications.org/bloodadv…
3
19
3
73
5,051
Our @CULymphoma lead Dr. @mana1981 just published a claims data analysis @BloodAdvances on CAR-T referral patterns in the United States. #lymsm #tcellrx pubmed.ncbi.nlm.nih.gov/4295…
2
9
423
Our T-cell lymphoma expert @CUAnschutz Dr. @BradHaverkos was interviewed on the @mghpetal #podcast about MRD monitoring in PTCL. #lymsm YouTube: youtu.be/0OcU_FcZph4 Spotify: spotifycreators-web.app.link… Apple: podcasts.apple.com/us/podcas…
On the PETAL Podcast, host @yumengzhang2009 of @MoffittNews, discusses molecular residual disease monitoring in peripheral T-cell lymphoma with Dr. Brad Haverkos of @CUSystem. 🌸 Listen now: youtu.be/0OcU_FcZph4 Also available on Spotify & Apple Podcasts.
3
5
400
CU Anschutz Lymphoma Program retweeted
On the PETAL Podcast, host @yumengzhang2009 of @MoffittNews, discusses molecular residual disease monitoring in peripheral T-cell lymphoma with Dr. Brad Haverkos of @CUSystem. 🌸 Listen now: youtu.be/0OcU_FcZph4 Also available on Spotify & Apple Podcasts.
2
2
4
466
CU Anschutz Lymphoma Program retweeted
Overseen by cardiologist Lavanya Kondapalli, MD, the University of Colorado Cardio-Oncology Program helps people with heart conditions undergoing treatment, as well as those who develop heart-related side effects from cancer therapies: bit.ly/4yu92Zc
1
2
191
Our @CUHematology lymphoma faculty Drs. @majorajay & @StevenBairMD contribute to the national CUBIC Consortium, with their latest publication on real-world outcomes of mosunetuzumab in indolent lymphomas now published @BloodPortfolio. #lymsm ashpublications.org/bloodneo…
1
8
679